Quoin Pharmaceuticals Files U.S. Patent Application for Novel Topical Formulations to Treat Netherton Syndrome and Other Skin Diseases

Core Viewpoint - Quoin Pharmaceuticals Ltd. has filed a U.S. patent application for novel topical formulations aimed at treating skin diseases, including Netherton Syndrome, with its lead product QRX003 currently undergoing clinical trials [1][2]. Group 1: Product Development - QRX003 is being tested in four clinical trials for Netherton Syndrome, with three trials under an open Investigational New Drug (IND) application with the FDA [1][3]. - Initial positive clinical data has been reported from two open-label studies related to QRX003 [1]. - The company is also conducting an Investigator Clinical Study for Peeling Skin Syndrome in a pediatric patient in New Zealand [1]. Group 2: Patent Protection - The patent application aims to provide broad protection for QRX003 until 2045, covering both Netherton Syndrome and other rare skin diseases [2][7]. - The CEO emphasized the importance of securing extensive patent protection for the product and related applications [2]. Group 3: Market Position - Quoin is currently the only company actively recruiting and testing subjects in multiple clinical trials for Netherton Syndrome under an open IND [3]. - The company is committed to addressing unmet medical needs for rare and orphan diseases, with a pipeline that includes five products targeting various conditions [5].